Form of Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Young and Older Adults

November 2, 2020 updated by: G. Harvey Anderson, University of Toronto

The Effect of Solid, Semi-solid and Liquid Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Young and Older Adults

The proposed study is planned to determine the potential role for regular fat dairy products in short-term metabolic control in younger and older adults and the metabolic flexibility in response to food components, which are areas that have not yet been explored. Subjects would be served with solid (cheese), semi-solid (yogurt) and liquid (milk) dairy products and skim milk (control) and water (non-caloric control) in three separate studies.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Over the last 30 years, overweight and obesity have become characteristic of the majority of Canadians. Approximately 60% of adults in Canada are overweight or obese. The Canadian Health Measures Survey, conducted during 2007-2009, estimated prevalence of metabolic syndrome at 19.1% in the adult population. In addition, according to the 2010 Canadian Community Health Survey, 18.1% of Canadian adults have been reported obese. Along with the health burden, it has also brought about an estimated economic burden of $ 4.3 billion annually in 2001, which has likely doubled as of today.

Metabolic syndrome and type 2 diabetes occur concurrently with insulin resistance marked by increased blood glucose levels at fasting and postprandial, glycosylated blood proteins leading to arterial damage, inflammation and comorbidities such as cardiovascular disease. Despite increased consumer interest in consuming foods that may help treat or prevent obesity and diabetes, effective countermeasures against metabolic diseases have yet to be established. Thus, food products that are capable of controlling parameters of metabolic diseases including blood glucose, insulin levels and food intake are in urgent need of investigation and identification. Dairy products are believed to hold this potential because of their functional physiological properties.

There have been many observational and long-term clinical studies showing that regular consumption of dairy products correlate with a better body composition and a lower incidence of obesity and type 2 diabetes. Studies have also found that dairy proteins are more satiating than other types of proteins, and that they are effective in lowering the increase in glycemic response after high GI food intake, but most studies have been done in isolated proteins. Hence, the role of dairy proteins, in their conventional food form reflecting usual intake, on food intake and glycemia and their interactions with these metabolic diseases is of interest.

From short-term studies done in our lab, the investigators have shown that dairy products can bring about benefits in glycemic control and food intake when consumed before or within ad libitum meals, which can be achieved by both insulin dependent and independent mechanisms. The investigators have shown that fluid milk products and yogurt improve post-meal glycemic excursions when consumed before or within an ad libitum meal by healthy young adults. Except the yogurt study conducted in our lab, there have been no other studies reporting the role of solid or semi-solid dairy products consumed before a meal, within a meal, immediately post-meal or as between meal snacks on glycemia and appetite control. Our study on yogurt showed that yogurts, especially those with high protein to carbohydrate ratio, reduced pre-meal glucose incremental areas under the curve. Further studies on solid and semi-solid dairy need to be conducted because milk, like other caloric beverages, lead to calorie accumulation if consumed before or with a meal even though it provides more nutrients, lowers post-meal blood glucose excursions and leads to greater post-meal satiety in young adults.

Moreover, the evidence appears to be relatively consistent with respect to a beneficial role of low-fat dairy products in the prevention of type 2 diabetes (T2D), however, the role of regular/high-fat dairy is less clear. A number of cross-sectional and prospective epidemiological studies have identified a positive association between the intake of dietary fat and the risk for development of either insulin resistance or T2D20. More research is needed to better understand the role of regular-fat dairy products on food intake as well as of glycemic control.

Three studies are proposed:

  • Study 1 investigates the effects of 2-servings of pre-meal regular fat; cheese, yogurt and milk on food intake at 2 hours, satiety and glycemia in normal weight young adults (20-30 yrs) and normal weight/overweight older adults (60-70 yrs).
  • Study 2 investigates the effects of 1-serving of pre-meal regular fat; cheese, yogurt and milk on satiety and glycemia in normal weight young adults (20-30 yrs) and normal weight/overweight older adults (60-70 yrs).
  • Study 3 investigate the effects of 1 serving for pre-meal regular fat; cheese, yogurt and milk on food intake at 15 min and 30 min, satiety and glycemia in normal weight/overweight older adults (60-70 yrs).

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5S 3E2
        • Department of Nutritional Sciences, FitzGerald Building

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy, non-smoking male and female participants aged 20-30 and 60-70 years old
  • Young adults with body mass index (BMI) of 18.5-24.9 kg/m2 (normal weight) and older adults with BMI between 18.5-29.9 kg/m2 (normal/overweight).

Exclusion Criteria:

  • Diabetic
  • Individuals on medication affecting appetite
  • Lactose-intolerant or allergic to dairy (including milk, yogurt, and cheese)
  • Breakfast skippers
  • Gastrointestinal problems
  • Individuals on an energy-restricted diet

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 3.25% M.F. Milk
All arms are given to all participants, in a randomized order
Experimental: Greek Yogurt
Greek Yogurt (2% M.F.)
All arms are given to all participants, in a randomized order
Experimental: Cheddar Cheese
Regular Fat Cheddar Cheese
All arms are given to all participants, in a randomized order
Experimental: Control 1
Skim milk
All arms are given to all participants, in a randomized order
Experimental: Control 2
Filtered water, calorie-free control
All arms are given to all participants, in a randomized order

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Glucose (Study 1, 2 and 3)
Time Frame: Post-treatment and post-meal

Blood glucose (mmol/L) is measured by using finger prick capillary blood samples.

Time frame and frequency vary for each study.

Study 1: Baseline measure (0 minute) then every 15 minutes up to 120 min (post-treatment), 8 times; 140 to 170 min (post-meal) every 30 mintes, 2 times . A total of 10 times

Study 2: Baseline measure (0 minute) then post-treatment every 15 minutes up to 90 minutes and last measure at 120 minutes. A total of 7 times.

Study 3: Part 1: Baseline measure (0 minute) then every 15 minutes up to 30 minutes post-treatment, then 50 minutes and every 15 minutes until 125 minutes. A total of 9 times.

Part 2: Baseline measure (0 minute) then at 15 post-treatment and, 35 and 50 minutes post-meal. A total of 4 times

Post-treatment and post-meal

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gastrointestinal hormones (Study 1)
Time Frame: Post-treatment and post-meal

Gatrointestinal hormones measured include plasma concentrations of glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY), cholecystokinin (CCK), and ghrelin.

Study 1: Baseline measure (0 minute) then every 30 minutes up to 60 minutes and then at 120 minutes (post-treatment), 4 times; 140 to 170 min (post-meal) every 30 minutes, 2 times . A total of 6 times

Post-treatment and post-meal
Serum Insulin (Study 1 and 2)
Time Frame: Post-treatment and post-meal

Serum Insulin (mIU/mL) is measured using blood collected through indwelling intravenous catheter (Study 1) and capillary blood into microvettes (Study 2)

Study 1: Baseline measure (0 minute) then every 30 minutes up to 60 minutes and then at 120 minutes (post-treatment), 4 times; 140 to 170 min (post-meal) every 30 minutes, 2 times . A total of 6 times

Study 2: Baseline measure (0 minute) then every 30 minutes up to 120 minutes post-treatment. A total of 5 times.

Post-treatment and post-meal
Subjective appetite (Study 1, 2 and 3)
Time Frame: Post-treatment and post-meal

Subjective appetite is measured by using visual analogue scales. Participants are instructed to mark and "x" anywhere along a 100 mm line that best reflects their feelings.

Time frame and frequency vary for each study.

Study 1: Baseline measure (0 minute) then every 15 minutes up to 120 min (post-treatment), 8 times; 140 to 170 min (post-meal) every 30 minutes, 2 times . A total of 10 times

Study 2: Baseline measure (0 minute) then every 15 minutes up to 120 minutes and last two measures are 30 minutes apart at 140 and 170 post-treatment. A total of 10 times.

Study 3: Part 1: Baseline measure (0 minute) then every 15 minutes (post-treatment) up to 30 minutes, then post-meal at 50 minutes and every 15 minutes until 125 minutes. A total of 9 times.

Part 2: Baseline measure (0 minute) then at 15 post-treatment and post-meal at 35, and 50 minutes. A total of 4 times.

Post-treatment and post-meal
Food Intake Measured at 120 minutes (Study 1), and at 15 and 30 minutes (Study 3)
Time Frame: Measurement done over 20 minutes
Food intake (kcal) is assessed post-treatment at 120 min (Study 1), 15 and 30 minutes (Study 3) after consumption of the treatments using an ad libitum pizza meal design. Participants are asked to eat until feeling comfortably over a 20 minute period.
Measurement done over 20 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2015

Primary Completion (Actual)

February 21, 2018

Study Completion (Actual)

February 21, 2018

Study Registration Dates

First Submitted

July 2, 2015

First Submitted That Met QC Criteria

July 7, 2015

First Posted (Estimate)

July 8, 2015

Study Record Updates

Last Update Posted (Actual)

November 3, 2020

Last Update Submitted That Met QC Criteria

November 2, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Dietary intervention

3
Subscribe